Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Failing Hearts Switch Fuels to Continue Generating Energy

By LabMedica International staff writers
Posted on 24 Feb 2016
A new study provides fresh biochemical insight into heart failure and may eventually lead to new diagnostic and pathology tests as well as therapeutic targets to prevent or slow progression of the disease. More...
The findings suggest a new approach to help treat early stages.

The research was led by Daniel Kelly, MD, scientific director of the Lake Nona campus of Sanford Burnham Prebys Medical Discovery Institute (SPB; La Jolla, CA & Lake Nona, FA, USA) as a collaborative study by scientists from SPB, Duke University, University of Illinois, and University of Cologne.

“Our research shows that as the heart fails, it loses its ability to burn fatty acids—the building blocks of fat—and instead starts using ketone bodies as an alternative fuel. It’s almost like the heart is starving because it doesn’t have the enzymatic machinery to burn fat anymore,” said Dr. Kelly.

To better understand what metabolic changes occur in place of fatty acid-burning, the team studied well established mouse models of the early and late stages of heart failure. They analyzed heart muscle cells to identify enzymes involved in metabolizing fuel that may ultimately become targets for therapies. They found that levels of BDH1, an enzyme involved in ketone metabolism, were 2x as high in mice with both early stage and complete heart failure compared to normal animals.

“It was surprising that BDH1 was increased in the failing heart, because this is an enzyme that is involved in burning ketones,” said Dr. Kelly, “We find it more in brain and liver, but one wouldn’t expect it to be very active in the heart.”

The new results suggest that a heart in the midst of failure has the ability to reprogram itself to take in more ketones and use them in a lower oxygen consumption fuel metabolism than fatty acid metabolism. Future studies on whether this is a productive or a faulty adaptive fuel shift could lead to new therapeutic avenues. Improved treatments would also be good news as the prevalence of heart failure is expected to increase in the coming years.

The study was published January 27, 2016, in the journal Circulation.

Related Links:

Sanford Burnham Prebys Medical Discovery Institute



New
Gold Member
STI Test
Vivalytic MG, MH, UP/UU
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Manual Pipetting Aid
Pipette Controllers macro
New
Electrolyte Analyzer
CBS-4000 (CBS-400)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The method that profiles DNA methylation in cell-free DNA from a single blood sample to detect disease signals system-wide (photo courtesy of Shutterstock)

cfDNA Methylation Assay Enables Multi-Disease Detection from Single Blood Sample

Early, accurate detection of cancer and organ disease remains limited by cost, reliance on targeted mutation assays, and uncertainty about the signal’s tissue of origin. Many liquid biopsy approaches require... Read more

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more

Pathology

view channel
Image: Spatial characterization of immune–tumor interactions and treatment response across SCLC and extended phenotype models (Cristian Barrera et al, npj Precision Oncology (2026). DOI: 10.1038/s41698-025-01225-9)

AI Pathology Tool Predicts Chemotherapy Response in Small Cell Lung Cancer

Small cell lung cancer often presents at an extensive stage and progresses rapidly, leaving little time to tailor first-line therapy. Clinicians currently lack biomarkers to guide which patients will benefit... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.